Back to results
US 11,633,412 B2Granted
Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
AssigneeAbbott Laboratories
InventorsRachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
Life of this patent
Estimating the term…
Abstract
Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Claims26
A synthetic pediatric formula in powder or liquid form, wherein, when the formula is a liquid, the formula comprises
- from about 0.01 mg/mL to about 5 mg/mL of the human milk oligosaccharide 2′-fucosyllactose;
- from about 100 mg/L to about 425 mg/L of a long chain omega-6 fatty acid;
- from about 40 mg/L to about 185 mg/L of a long chain omega-3 fatty acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising at most two of lutein, lycopene, beta-carotene, or a combination thereof;
- from about 72 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component, wherein the monomeric monophosphate nucleotide component comprises at least one salt;
- wherein the ratio of long chain omega-6 fatty acids to long chain omega-3 fatty acids is from about 2:1 to about 3:1;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable for at least 3 months.
6 more elements
A synthetic pediatric formula in powder or liquid form, wherein, when the formula is a liquid, the formula comprises
- from about 0.01 mg/mL to about 5 mg/mL of the human milk oligosaccharide 2′-fucosyllactose;
- from about 100 mg/L to about 425 mg/L of a long chain omega-6 fatty acid;
- from about 40 mg/L to about 185 mg/L of a long chain omega-3 fatty acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising at most two of lutein, lycopene, beta-carotene, or a combination thereof;
- from about 72 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component, wherein the monomeric monophosphate nucleotide component comprises at least one salt;
- additional nutritional components comprising high oleic safflower oil, soybean oil, coconut oil, or a combination thereof;
- wherein the ratio of long chain omega-6 fatty acids to long chain omega-3 fatty acids is from about 2:1 to about 3:1;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable from about 6 months to about 24 months.
7 more elements
A synthetic pediatric formula in powder or liquid form, wherein, when the formula is a liquid, the formula comprises
- from about 0.01 mg/mL to about 5 mg/mL of the human milk oligosaccharide 2′-fucosyllactose;
- from about 100 mg/L to about 425 mg/L of a long chain omega-6 fatty acid;
- from about 40 mg/L to about 185 mg/L of a long chain omega-3 fatty acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising at most two of lutein, lycopene, beta-carotene, or a combination thereof;
- from about 72 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component, wherein the monomeric monophosphate nucleotide component comprises at least one salt;
- additional nutritional components comprising whey protein, lactose, fructooligosaccharide, or a combination thereof;
- wherein the ratio of long chain omega-6 fatty acids to long chain omega-3 fatty acids is from about 2:1 to about 3:1;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable from about 12 months to about 18 months.
7 more elements
A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, child or toddler a synthetic pediatric formula comprising:
- from about 0.01 mg/mL to about 5 mg/mL of the human milk oligosaccharide 2′-fucosyllactose;
- from about 100 mg/L to about 425 mg/L of a long chain omega-6 fatty acid;
- from about 40 mg/L to about 185 mg/L of a long chain omega-3 fatty acid;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising at most two of lutein, lycopene, beta-carotene, or a combination thereof;
- from about 72 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component, wherein the monomeric monophosphate nucleotide component comprises at least one salt;
- wherein the ratio of long chain omega-6 fatty acids to long chain omega-3 fatty acids is from about 2:1 to about 3:1;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic pediatric formula is shelf stable from about 12 months to about 18 months.
6 more elements
Dependencies are inferred from the claim text.